RU2603637C2 - Замещённые пиразолопиримидины как активаторы глюкоцереброзидазы - Google Patents
Замещённые пиразолопиримидины как активаторы глюкоцереброзидазы Download PDFInfo
- Publication number
- RU2603637C2 RU2603637C2 RU2013126094/04A RU2013126094A RU2603637C2 RU 2603637 C2 RU2603637 C2 RU 2603637C2 RU 2013126094/04 A RU2013126094/04 A RU 2013126094/04A RU 2013126094 A RU2013126094 A RU 2013126094A RU 2603637 C2 RU2603637 C2 RU 2603637C2
- Authority
- RU
- Russia
- Prior art keywords
- carboxamide
- pyrimidine
- difluoromethyl
- dihydropyrazolo
- alkyl
- Prior art date
Links
- 108010017544 Glucosylceramidase Proteins 0.000 title claims abstract description 20
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title abstract description 10
- 102000004547 Glucosylceramidase Human genes 0.000 title description 14
- 239000012190 activator Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 22
- 208000015872 Gaucher disease Diseases 0.000 claims abstract description 19
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- HVZPJBKUFRREQC-UHFFFAOYSA-N n-(4-ethynylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(C#C)C=C1 HVZPJBKUFRREQC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 101150028412 GBA gene Proteins 0.000 claims abstract description 7
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- -1 [1,3] dioxolyl Chemical group 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 49
- 125000001424 substituent group Chemical group 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000004193 piperazinyl group Chemical group 0.000 claims description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 8
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 7
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 7
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- YSSQOFFSTKULPW-UHFFFAOYSA-N n-(4-ethylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 YSSQOFFSTKULPW-UHFFFAOYSA-N 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 4
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 claims 3
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 2
- KMOYDBZAUGGJNC-UHFFFAOYSA-N 7-(difluoromethyl)-n-(4-ethylphenyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C(F)F)N2N=C1 KMOYDBZAUGGJNC-UHFFFAOYSA-N 0.000 claims 2
- YHAVWNXZFBVYOJ-UHFFFAOYSA-N chembl1725455 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=CC=C1SC1=CC=CC=C1 YHAVWNXZFBVYOJ-UHFFFAOYSA-N 0.000 claims 2
- NBVXSTLIUNQXBT-UHFFFAOYSA-N chembl3185251 Chemical compound CCOC1=CC=CC=C1NC(=O)C1=C(NC(=C)C=C2C(F)F)N2N=C1 NBVXSTLIUNQXBT-UHFFFAOYSA-N 0.000 claims 2
- UYRSGEMAVXKNAN-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(Cl)C(Cl)=C1 UYRSGEMAVXKNAN-UHFFFAOYSA-N 0.000 claims 2
- MCQYBGOYJAACFA-UHFFFAOYSA-N n-(4-tert-butylcyclohexyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1CCC(C(C)(C)C)CC1 MCQYBGOYJAACFA-UHFFFAOYSA-N 0.000 claims 2
- IVHLMTIZKQNVGP-UHFFFAOYSA-N n-(4-tert-butylcyclohexyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C)=CC(C=3C=CC=CC=3)=NC2=C1C(=O)NC1CCC(C(C)(C)C)CC1 IVHLMTIZKQNVGP-UHFFFAOYSA-N 0.000 claims 2
- ZRJZMBZYIIHIKP-UHFFFAOYSA-N (5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=C2N=C(C)C=C(C)N2N=C1 ZRJZMBZYIIHIKP-UHFFFAOYSA-N 0.000 claims 1
- KLFXDMIVOKQLJQ-UHFFFAOYSA-N (5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-[4-(4-nitrophenyl)piperazin-1-yl]methanone Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)N(CC1)CCN1C1=CC=C([N+]([O-])=O)C=C1 KLFXDMIVOKQLJQ-UHFFFAOYSA-N 0.000 claims 1
- HQECLAJCHXWXHB-UHFFFAOYSA-N (5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-pyrrolidin-1-ylmethanone Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)N1CCCC1 HQECLAJCHXWXHB-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- JMBFLTLAOSJEEW-UHFFFAOYSA-N 5,7-dimethyl-N-(3,4,5-trimethoxyphenyl)-3-pyrazolo[1,5-a]pyrimidinecarboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C2=C3N=C(C)C=C(C)N3N=C2)=C1 JMBFLTLAOSJEEW-UHFFFAOYSA-N 0.000 claims 1
- CGRNXIVXFQQADA-UHFFFAOYSA-N 5,7-dimethyl-n-(2-methylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=CC=C1C CGRNXIVXFQQADA-UHFFFAOYSA-N 0.000 claims 1
- NICJTSHRYBTHAS-UHFFFAOYSA-N 5,7-dimethyl-n-(2-methylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=CC(C)=NC2=C(C(=O)NCC(C)C)C=NN21 NICJTSHRYBTHAS-UHFFFAOYSA-N 0.000 claims 1
- YZZVXMLMYKWHNE-UHFFFAOYSA-N 5,7-dimethyl-n-(4-methylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 YZZVXMLMYKWHNE-UHFFFAOYSA-N 0.000 claims 1
- ONGSAYSLHZBWEP-UHFFFAOYSA-N 5,7-dimethyl-n-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=CC(C(F)(F)F)=C1 ONGSAYSLHZBWEP-UHFFFAOYSA-N 0.000 claims 1
- YBKYTNNBXFZNFF-UHFFFAOYSA-N 5,7-dimethyl-n-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(C(F)(F)F)C=C1 YBKYTNNBXFZNFF-UHFFFAOYSA-N 0.000 claims 1
- XCIDHWANBYVQSB-UHFFFAOYSA-N 5,7-dimethyl-n-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=CC=C1 XCIDHWANBYVQSB-UHFFFAOYSA-N 0.000 claims 1
- HMIGLJHJZOAEQL-UHFFFAOYSA-N 5,7-dimethyl-n-propan-2-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=CC(C)=NC2=C(C(=O)NC(C)C)C=NN21 HMIGLJHJZOAEQL-UHFFFAOYSA-N 0.000 claims 1
- OPYMGGPOPIVVNR-UHFFFAOYSA-N 5-cyclopropylidene-7-(difluoromethyl)-N-(1-methylpiperidin-4-yl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 OPYMGGPOPIVVNR-UHFFFAOYSA-N 0.000 claims 1
- CYEFRDZGYTWHFV-UHFFFAOYSA-N 5-cyclopropylidene-7-(difluoromethyl)-N-(3,4-difluorophenyl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=C(F)C(F)=C1 CYEFRDZGYTWHFV-UHFFFAOYSA-N 0.000 claims 1
- GTZRFXVCWJKLEH-UHFFFAOYSA-N 5-cyclopropylidene-7-(difluoromethyl)-N-(6-methylpyridin-2-yl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=CC=CC(NC(=O)C2=C3N(C(=CC(N3)=C3CC3)C(F)F)N=C2)=N1 GTZRFXVCWJKLEH-UHFFFAOYSA-N 0.000 claims 1
- GZJZTGQDRYURCA-UHFFFAOYSA-N 5-cyclopropylidene-7-(difluoromethyl)-N-[(1-methylpyrazol-4-yl)methyl]-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN(C)C=C1CNC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 GZJZTGQDRYURCA-UHFFFAOYSA-N 0.000 claims 1
- XFZIBFQRHNQJHW-UHFFFAOYSA-N 5-cyclopropylidene-7-(difluoromethyl)-N-pyridin-3-yl-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=CN=C1 XFZIBFQRHNQJHW-UHFFFAOYSA-N 0.000 claims 1
- PFBZJDASYDABLN-UHFFFAOYSA-N 5-cyclopropylidene-N-(3,5-dichlorophenyl)-7-(difluoromethyl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC(Cl)=CC(Cl)=C1 PFBZJDASYDABLN-UHFFFAOYSA-N 0.000 claims 1
- MUFXADBLCQQICZ-UHFFFAOYSA-N 5-methyl-n-(4-methylphenyl)-7-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C=3C=CC=CC=3)N2N=C1 MUFXADBLCQQICZ-UHFFFAOYSA-N 0.000 claims 1
- SVBPNHUWOFJWEG-UHFFFAOYSA-N 5-methyl-n-[4-(trifluoromethyl)phenyl]-6,7,8,9-tetrahydropyrazolo[1,5-a]quinazoline-3-carboxamide Chemical compound C1=NN2C=3CCCCC=3C(C)=NC2=C1C(=O)NC1=CC=C(C(F)(F)F)C=C1 SVBPNHUWOFJWEG-UHFFFAOYSA-N 0.000 claims 1
- YDKKMPMIQSIIKC-UHFFFAOYSA-N 7-(difluoromethyl)-5-methyl-n-(4-methylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C(F)F)N2N=C1 YDKKMPMIQSIIKC-UHFFFAOYSA-N 0.000 claims 1
- VCRFPNNYMJNLSQ-UHFFFAOYSA-N 7-(difluoromethyl)-5-methyl-n-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C(F)F)N2N=CC=1C(=O)NC1=CC=C(C(F)(F)F)C=C1 VCRFPNNYMJNLSQ-UHFFFAOYSA-N 0.000 claims 1
- YBSJLAJXNRBCFV-UHFFFAOYSA-N 7-(difluoromethyl)-5-methylidene-N-[[2-(trifluoromethyl)phenyl]methyl]-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCC1=CC=CC=C1C(F)(F)F YBSJLAJXNRBCFV-UHFFFAOYSA-N 0.000 claims 1
- GYTXCTZGTSUBPR-UHFFFAOYSA-N 7-(difluoromethyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methylidene-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)C1=C(NC(=C)C=C2C(F)F)N2N=C1 GYTXCTZGTSUBPR-UHFFFAOYSA-N 0.000 claims 1
- WICPNVMYTPNMIV-UHFFFAOYSA-N 7-(difluoromethyl)-n-(4-ethynylphenyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C(F)F)N2N=CC=1C(=O)NC1=CC=C(C#C)C=C1 WICPNVMYTPNMIV-UHFFFAOYSA-N 0.000 claims 1
- XUGXXWWPSTYHED-UHFFFAOYSA-N 7-(difluoromethyl)-n-[1-[(4-fluorophenyl)methyl]pyrazol-4-yl]-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(C=3C=CC=CC=3)=NC2=C1C(=O)NC(=C1)C=NN1CC1=CC=C(F)C=C1 XUGXXWWPSTYHED-UHFFFAOYSA-N 0.000 claims 1
- VCRLHFWEGPKVQW-UHFFFAOYSA-N N,N-dicyclohexyl-5-cyclopropylidene-7-(difluoromethyl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)N(C1CCCCC1)C1CCCCC1 VCRLHFWEGPKVQW-UHFFFAOYSA-N 0.000 claims 1
- FYMHBWNKWMMBPY-UHFFFAOYSA-N N-(2,3-dihydro-1,4-benzodioxin-6-yl)-5,7-dimethyl-3-pyrazolo[1,5-a]pyrimidinecarboxamide Chemical compound O1CCOC2=CC(NC(=O)C=3C=NN4C(C)=CC(=NC4=3)C)=CC=C21 FYMHBWNKWMMBPY-UHFFFAOYSA-N 0.000 claims 1
- IJHKKHPENYDANX-UHFFFAOYSA-N N-(2,3-dihydro-1H-inden-5-yl)-5,7-dimethyl-3-pyrazolo[1,5-a]pyrimidinecarboxamide Chemical compound C1=C2CCCC2=CC(NC(=O)C=2C=NN3C(C)=CC(=NC3=2)C)=C1 IJHKKHPENYDANX-UHFFFAOYSA-N 0.000 claims 1
- KDXQSDAPHUEXSJ-UHFFFAOYSA-N N-(3-acetylphenyl)-5,7-dimethyl-3-pyrazolo[1,5-a]pyrimidinecarboxamide Chemical compound CC(=O)C1=CC=CC(NC(=O)C2=C3N=C(C)C=C(C)N3N=C2)=C1 KDXQSDAPHUEXSJ-UHFFFAOYSA-N 0.000 claims 1
- OEPHUHZIEWQNMV-UHFFFAOYSA-N N-(4-bromo-2-chlorophenyl)-5-cyclopropylidene-7-(difluoromethyl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=C(Br)C=C1Cl OEPHUHZIEWQNMV-UHFFFAOYSA-N 0.000 claims 1
- YLOVOAWHCHJWRE-UHFFFAOYSA-N N-(4-bromophenyl)-5-cyclopropylidene-7-(difluoromethyl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=C(Br)C=C1 YLOVOAWHCHJWRE-UHFFFAOYSA-N 0.000 claims 1
- GGBNAHMOTCFJHS-UHFFFAOYSA-N N-(5-bromopyridin-2-yl)-5-cyclopropylidene-7-(difluoromethyl)-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=C(Br)C=N1 GGBNAHMOTCFJHS-UHFFFAOYSA-N 0.000 claims 1
- XLUAAOIBRIUDQP-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-7-(difluoromethyl)-5-methylidene-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCC1=CC=CC=C1Cl XLUAAOIBRIUDQP-UHFFFAOYSA-N 0.000 claims 1
- ZFIIFXLGSQPYGE-UHFFFAOYSA-N N-[(4-chlorophenyl)methyl]-7-(difluoromethyl)-5-methylidene-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCC1=CC=C(Cl)C=C1 ZFIIFXLGSQPYGE-UHFFFAOYSA-N 0.000 claims 1
- LTMDNLJNRQSOEA-UHFFFAOYSA-N N-[2-(2-chlorophenyl)ethyl]-7-(difluoromethyl)-5-methylidene-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCCC1=CC=CC=C1Cl LTMDNLJNRQSOEA-UHFFFAOYSA-N 0.000 claims 1
- PWYSFEDEWYZHQH-UHFFFAOYSA-N [7-(difluoromethyl)-5-methylidene-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)N(CC1)CCN1C1=CC=CC=N1 PWYSFEDEWYZHQH-UHFFFAOYSA-N 0.000 claims 1
- XMBVLXDWUPESNP-UHFFFAOYSA-N [7-(difluoromethyl)-5-methylidene-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-piperidin-1-ylmethanone Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)N1CCCCC1 XMBVLXDWUPESNP-UHFFFAOYSA-N 0.000 claims 1
- 125000005011 alkyl ether group Chemical group 0.000 claims 1
- HTBKKXHYVBAOLT-UHFFFAOYSA-N chembl1700435 Chemical compound C1=CC(C(C)CC)=CC=C1NC(=O)C1=C(NC(=C)C=C2C(F)F)N2N=C1 HTBKKXHYVBAOLT-UHFFFAOYSA-N 0.000 claims 1
- BLWPNCPHSRWMOK-UHFFFAOYSA-N chembl1714232 Chemical compound N1C2=C(C(=O)NC=3C=C4CCCC4=CC=3)C=NN2C(C(F)F)=CC1=C1CC1 BLWPNCPHSRWMOK-UHFFFAOYSA-N 0.000 claims 1
- XPZTZQKJXDOKPR-UHFFFAOYSA-N chembl1716885 Chemical compound C1=NN2C(C(F)(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=CC=C1SC1=CC=CC=C1 XPZTZQKJXDOKPR-UHFFFAOYSA-N 0.000 claims 1
- IUJQOWDONOIJRD-UHFFFAOYSA-N chembl1723999 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1CCCCC1 IUJQOWDONOIJRD-UHFFFAOYSA-N 0.000 claims 1
- ZJTWTDPHRBJXQN-UHFFFAOYSA-N chembl1867541 Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 ZJTWTDPHRBJXQN-UHFFFAOYSA-N 0.000 claims 1
- AAWGXKDFFFEINN-UHFFFAOYSA-N chembl1870221 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=CN=C1Cl AAWGXKDFFFEINN-UHFFFAOYSA-N 0.000 claims 1
- WFCTUWCTLULDLZ-UHFFFAOYSA-N chembl1874145 Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 WFCTUWCTLULDLZ-UHFFFAOYSA-N 0.000 claims 1
- MUEZEYDZQXQLNT-UHFFFAOYSA-N chembl1876337 Chemical compound N1=CC=C2C(NC(=O)C3=C4NC(=C)C=C(N4N=C3)C)=CC=CC2=C1 MUEZEYDZQXQLNT-UHFFFAOYSA-N 0.000 claims 1
- YRUSMPLCKKPXOR-UHFFFAOYSA-N chembl1878874 Chemical compound C1=CC(N(CC)CC)=CC=C1NC(=O)C1=C(NC(=C)C=C2C(F)F)N2N=C1 YRUSMPLCKKPXOR-UHFFFAOYSA-N 0.000 claims 1
- BFGMJVMDZAXEHA-UHFFFAOYSA-N chembl1881090 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=CC=C1Br BFGMJVMDZAXEHA-UHFFFAOYSA-N 0.000 claims 1
- OHSZLQMKXVFEFE-UHFFFAOYSA-N chembl1881290 Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCC1=CC=C(Cl)C=C1Cl OHSZLQMKXVFEFE-UHFFFAOYSA-N 0.000 claims 1
- RLJJHFBZZBETKS-UHFFFAOYSA-N chembl1885887 Chemical compound C1=NN2C(C)=CC(=C)NC2=C1C(=O)NC1=CC=CC=C1O RLJJHFBZZBETKS-UHFFFAOYSA-N 0.000 claims 1
- LGECWDNOBJRGIQ-UHFFFAOYSA-N chembl1886380 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=C(Br)C=C1F LGECWDNOBJRGIQ-UHFFFAOYSA-N 0.000 claims 1
- OJSDGCOLPKPYAZ-UHFFFAOYSA-N chembl1887267 Chemical compound C1CC(C(C)(C)C)CCC1NC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 OJSDGCOLPKPYAZ-UHFFFAOYSA-N 0.000 claims 1
- IOKDCCFJHGEPMK-UHFFFAOYSA-N chembl1887655 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=CC=C1F IOKDCCFJHGEPMK-UHFFFAOYSA-N 0.000 claims 1
- GJUOWWGQGDXQBK-UHFFFAOYSA-N chembl1890316 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=C(Cl)C=C1Cl GJUOWWGQGDXQBK-UHFFFAOYSA-N 0.000 claims 1
- SLTFOEOKASZUFK-UHFFFAOYSA-N chembl1892410 Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCC1=CC=CC=C1F SLTFOEOKASZUFK-UHFFFAOYSA-N 0.000 claims 1
- JGMFTAOWKMQNDT-UHFFFAOYSA-N chembl1895042 Chemical compound C1=NN2C(C)=CC(=C)NC2=C1C(=O)NC1=CC=C(C)C=N1 JGMFTAOWKMQNDT-UHFFFAOYSA-N 0.000 claims 1
- QVYFBFVOINQVSX-UHFFFAOYSA-N chembl1895843 Chemical compound C1=CC(C)=CC=C1NC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 QVYFBFVOINQVSX-UHFFFAOYSA-N 0.000 claims 1
- ZOPRAITYHAXVHL-UHFFFAOYSA-N chembl1896615 Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=C(NC(C=C2C(F)(F)F)=C3CC3)N2N=C1 ZOPRAITYHAXVHL-UHFFFAOYSA-N 0.000 claims 1
- OZPRMVXBPKAGKF-UHFFFAOYSA-N chembl1898529 Chemical compound N1C2=C(C(=O)NC=3C=C4OCCOC4=CC=3)C=NN2C(C(F)F)=CC1=C1CC1 OZPRMVXBPKAGKF-UHFFFAOYSA-N 0.000 claims 1
- FPERHLZSJYHHHP-UHFFFAOYSA-N chembl1898725 Chemical compound N1C(=C)C=C(C)N2C1=C(C(=O)NCCCCCC)C=N2 FPERHLZSJYHHHP-UHFFFAOYSA-N 0.000 claims 1
- MRZWTTHYDRPLGG-UHFFFAOYSA-N chembl1898939 Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 MRZWTTHYDRPLGG-UHFFFAOYSA-N 0.000 claims 1
- GLKUOMQUBDOYPC-UHFFFAOYSA-N chembl1900686 Chemical compound C1=C(C)C(C)=CC=C1NC(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 GLKUOMQUBDOYPC-UHFFFAOYSA-N 0.000 claims 1
- DBDUBCKWYJFUGG-UHFFFAOYSA-N chembl1900784 Chemical compound C=1C=NC=CC=1C(C)NC(=O)C=1C=NN(C(=C2)C(F)F)C=1NC2=C1CC1 DBDUBCKWYJFUGG-UHFFFAOYSA-N 0.000 claims 1
- LDRWLVPALRBOFK-UHFFFAOYSA-N chembl1901326 Chemical compound CCC1=CC=CC(NC(=O)C2=C3N(C(=CC(=C)N3)C(F)F)N=C2)=C1 LDRWLVPALRBOFK-UHFFFAOYSA-N 0.000 claims 1
- NYSUCFDGXPZAIB-UHFFFAOYSA-N chembl1901966 Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1=C2NC(=C)C=C(C(F)F)N2N=C1 NYSUCFDGXPZAIB-UHFFFAOYSA-N 0.000 claims 1
- SKRNYDJYGJJKSP-UHFFFAOYSA-N chembl1902051 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=C(Cl)C=C1 SKRNYDJYGJJKSP-UHFFFAOYSA-N 0.000 claims 1
- DRYVCCYVIZSNGK-UHFFFAOYSA-N chembl1905484 Chemical compound C1=NN2C(C)=CC(=C)NC2=C1C(=O)N(CC=1C=CC=CC=1)CCC1=CC=CC=C1 DRYVCCYVIZSNGK-UHFFFAOYSA-N 0.000 claims 1
- IWLGWKPBGMBXAA-UHFFFAOYSA-N chembl1965492 Chemical compound N1C2=C(C(=O)N3C4=CC=CC=C4CC3)C=NN2C(C(F)F)=CC1=C1CC1 IWLGWKPBGMBXAA-UHFFFAOYSA-N 0.000 claims 1
- JOBICGKYHJIXCI-UHFFFAOYSA-N chembl1972759 Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)N(CC1)CCN1C1=CC=CC=C1 JOBICGKYHJIXCI-UHFFFAOYSA-N 0.000 claims 1
- MNMLBKPEQUVIMJ-UHFFFAOYSA-N chembl1992849 Chemical compound C1CCC2=CC(C)=CC=C2N1C(=O)C=1C=NN(C(=C2)C(F)F)C=1NC2=C1CC1 MNMLBKPEQUVIMJ-UHFFFAOYSA-N 0.000 claims 1
- CJSKHBXNBHEUJC-UHFFFAOYSA-N chembl2354907 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1CCCC1 CJSKHBXNBHEUJC-UHFFFAOYSA-N 0.000 claims 1
- BRPCGRALTFUXMR-UHFFFAOYSA-N chembl2355809 Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCC1=CC=CC=C1 BRPCGRALTFUXMR-UHFFFAOYSA-N 0.000 claims 1
- BNZGRWSOFVPZMV-UHFFFAOYSA-N chembl2356111 Chemical compound C1=C(Cl)C(NC(=O)C)=CC=C1NC(=O)C1=C(NC(=C)C=C2C)N2N=C1 BNZGRWSOFVPZMV-UHFFFAOYSA-N 0.000 claims 1
- QZTIBCFHYWXKAA-UHFFFAOYSA-N chembl2356724 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC=NC=C1 QZTIBCFHYWXKAA-UHFFFAOYSA-N 0.000 claims 1
- LMTJFVMSNTYUSQ-UHFFFAOYSA-N chembl2358536 Chemical compound COC1=CC=CC=C1CNC(=O)C1=C(NC(=C)C=C2C(F)F)N2N=C1 LMTJFVMSNTYUSQ-UHFFFAOYSA-N 0.000 claims 1
- IABRXIIRBWPXRT-UHFFFAOYSA-N chembl2358922 Chemical compound N1C2=C(C(=O)N3CC4=CC=CC=C4CC3)C=NN2C(C(F)F)=CC1=C1CC1 IABRXIIRBWPXRT-UHFFFAOYSA-N 0.000 claims 1
- BAPNOZURPUDGIY-UHFFFAOYSA-N chembl2359282 Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=C(NC(=C)C=C2C(F)(F)F)N2N=C1 BAPNOZURPUDGIY-UHFFFAOYSA-N 0.000 claims 1
- AABGHFWXMGZNOV-UHFFFAOYSA-N chembl2359779 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC(C=1)=CC=CC=1NC1=CC=CC=C1 AABGHFWXMGZNOV-UHFFFAOYSA-N 0.000 claims 1
- FZMDQTDZGTULQW-UHFFFAOYSA-N chembl2360953 Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCCC1=CC=C(Cl)C=C1 FZMDQTDZGTULQW-UHFFFAOYSA-N 0.000 claims 1
- FTLHUAVVOHPWRC-UHFFFAOYSA-N chembl2361241 Chemical compound C1=NN2C(C(F)F)=CC(=C3CC3)NC2=C1C(=O)NC1=CC(F)=CC=C1F FTLHUAVVOHPWRC-UHFFFAOYSA-N 0.000 claims 1
- WJTDUTUTEKJDCL-UHFFFAOYSA-N chembl2361483 Chemical compound N1C2=C(C(=O)NC=3C4=CC=CC=C4C=CC=3)C=NN2C(C(F)F)=CC1=C1CC1 WJTDUTUTEKJDCL-UHFFFAOYSA-N 0.000 claims 1
- JMTYCVAJHIFHHT-UHFFFAOYSA-N chembl2361661 Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=C(NC(=C)C=C2C(F)F)N2N=C1 JMTYCVAJHIFHHT-UHFFFAOYSA-N 0.000 claims 1
- CEKDEBUNJBJAOI-UHFFFAOYSA-N chembl2361799 Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=C(NC(=C)C=C2C(F)F)N2N=C1 CEKDEBUNJBJAOI-UHFFFAOYSA-N 0.000 claims 1
- XMBQBGORODLEBS-UHFFFAOYSA-N chembl2361911 Chemical compound N1C2=C(C(=O)NC3C4=CC=CC=C4CCC3)C=NN2C(C(F)F)=CC1=C1CC1 XMBQBGORODLEBS-UHFFFAOYSA-N 0.000 claims 1
- XBTCOKVNCYIOPE-UHFFFAOYSA-N chembl2361992 Chemical compound C1=NN2C(C)=CC(=C)NC2=C1C(=O)NC(C=1)=CC=CC=1C(=O)NC1=CC=CC(C(F)(F)F)=C1 XBTCOKVNCYIOPE-UHFFFAOYSA-N 0.000 claims 1
- FEHJERVYRFYEKP-UHFFFAOYSA-N chembl2362278 Chemical compound C1=NN2C(C(F)F)=CC(=C)NC2=C1C(=O)NCC1=CC=C(F)C=C1 FEHJERVYRFYEKP-UHFFFAOYSA-N 0.000 claims 1
- KJMLNMNUMFIPCL-UHFFFAOYSA-N chembl2362622 Chemical compound CC1CCCCN1C(=O)C1=C(NC(C=C2C(F)F)=C3CC3)N2N=C1 KJMLNMNUMFIPCL-UHFFFAOYSA-N 0.000 claims 1
- KCXGXZZNLYRATG-UHFFFAOYSA-N chembl3185805 Chemical compound C1=NN2C(C)=CC(=C)NC2=C1C(=O)NC1=CC=C(F)C=C1F KCXGXZZNLYRATG-UHFFFAOYSA-N 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- WAJFVWHQNNSYSE-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=C2OCOC2=CC(NC(=O)C=2C=NN3C(C)=CC(=NC3=2)C)=C1 WAJFVWHQNNSYSE-UHFFFAOYSA-N 0.000 claims 1
- BAQRWBMMNKFXMM-UHFFFAOYSA-N n-(2,2-difluoroethyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N1=C(C)C=C(C)N2N=CC(C(=O)NCC(F)F)=C21 BAQRWBMMNKFXMM-UHFFFAOYSA-N 0.000 claims 1
- GORNGWMUZPULFD-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-5-yl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N=1C2=C(C(=O)NC=3C=C4CCCC4=CC=3)C=NN2C(C)=CC=1C1=CC=CC=C1 GORNGWMUZPULFD-UHFFFAOYSA-N 0.000 claims 1
- HRWXMWZGWFRMKS-UHFFFAOYSA-N n-(2,4-dimethoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound COC1=CC(OC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 HRWXMWZGWFRMKS-UHFFFAOYSA-N 0.000 claims 1
- BPALHJKTAIUBDV-UHFFFAOYSA-N n-(2,4-dimethylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=CC(C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 BPALHJKTAIUBDV-UHFFFAOYSA-N 0.000 claims 1
- QSACGBUNBSFHBK-UHFFFAOYSA-N n-(2-acetamidophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC(=O)NC1=CC=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 QSACGBUNBSFHBK-UHFFFAOYSA-N 0.000 claims 1
- JTGDZISSXYTCKS-UHFFFAOYSA-N n-(2-fluoro-4-methylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound FC1=CC(C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 JTGDZISSXYTCKS-UHFFFAOYSA-N 0.000 claims 1
- IZHOVQURYPJAAH-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N12N=CC(C(=O)NC=3C=C(Cl)C(Cl)=CC=3)=C2N=C(C)C=C1C1=CC=CC=C1 IZHOVQURYPJAAH-UHFFFAOYSA-N 0.000 claims 1
- POUWXDPADZXHFI-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-7-(difluoromethyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C(F)F)N2N=CC=1C(=O)NC1=CC=C(Cl)C(Cl)=C1 POUWXDPADZXHFI-UHFFFAOYSA-N 0.000 claims 1
- RYYDHHCIALXPJJ-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C)=CC(C=3C=CC=CC=3)=NC2=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 RYYDHHCIALXPJJ-UHFFFAOYSA-N 0.000 claims 1
- ZKRJBNNHAFUZBR-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 ZKRJBNNHAFUZBR-UHFFFAOYSA-N 0.000 claims 1
- BUNCVWLLILEPDT-UHFFFAOYSA-N n-(3,4-dimethylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(C)C(C)=C1 BUNCVWLLILEPDT-UHFFFAOYSA-N 0.000 claims 1
- YGMNTZSJEHOSOI-UHFFFAOYSA-N n-(3,5-dichlorophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC(Cl)=CC(Cl)=C1 YGMNTZSJEHOSOI-UHFFFAOYSA-N 0.000 claims 1
- PXKASVTZTWTBHJ-UHFFFAOYSA-N n-(3,5-difluorophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC(F)=CC(F)=C1 PXKASVTZTWTBHJ-UHFFFAOYSA-N 0.000 claims 1
- CMJTXCYZMCIKRS-UHFFFAOYSA-N n-(3-bromophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=CC(Br)=C1 CMJTXCYZMCIKRS-UHFFFAOYSA-N 0.000 claims 1
- BMMBPKFMILAVTI-UHFFFAOYSA-N n-(3-chloro-4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=C(Cl)C(OC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 BMMBPKFMILAVTI-UHFFFAOYSA-N 0.000 claims 1
- BNOBIRVTPPJCRY-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(C)C(Cl)=C1 BNOBIRVTPPJCRY-UHFFFAOYSA-N 0.000 claims 1
- UCBWFHZNACICJG-UHFFFAOYSA-N n-(3-cyanophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=CC(C#N)=C1 UCBWFHZNACICJG-UHFFFAOYSA-N 0.000 claims 1
- RKTYVXCESFVUKW-UHFFFAOYSA-N n-(3-fluoro-4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=C(F)C(OC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 RKTYVXCESFVUKW-UHFFFAOYSA-N 0.000 claims 1
- MEVUEOGLFRQFQI-UHFFFAOYSA-N n-(3-hydroxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=CC(O)=C1 MEVUEOGLFRQFQI-UHFFFAOYSA-N 0.000 claims 1
- GUBFWHDFZJSMKW-UHFFFAOYSA-N n-(4-acetamidophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(NC(=O)C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 GUBFWHDFZJSMKW-UHFFFAOYSA-N 0.000 claims 1
- UEAZOKNNUSCPBI-UHFFFAOYSA-N n-(4-acetylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 UEAZOKNNUSCPBI-UHFFFAOYSA-N 0.000 claims 1
- MXUJAPVDZMJYBX-UHFFFAOYSA-N n-(4-bromophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(Br)C=C1 MXUJAPVDZMJYBX-UHFFFAOYSA-N 0.000 claims 1
- ABJOULSMPYSQCA-UHFFFAOYSA-N n-(4-butan-2-ylphenyl)-7-(difluoromethyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(C(C)CC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C(F)F)N2N=C1 ABJOULSMPYSQCA-UHFFFAOYSA-N 0.000 claims 1
- BLOQLAGLYRHRFK-UHFFFAOYSA-N n-(4-cyanophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(C#N)C=C1 BLOQLAGLYRHRFK-UHFFFAOYSA-N 0.000 claims 1
- DQUDCBPQSRYTTL-UHFFFAOYSA-N n-(4-ethylphenyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C=3C=CC=CC=3)N2N=C1 DQUDCBPQSRYTTL-UHFFFAOYSA-N 0.000 claims 1
- AIUVRXYMVLUFQP-UHFFFAOYSA-N n-(4-ethylphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)C1=C2N=C(C=3C=CC=CC=3)C=C(C)N2N=C1 AIUVRXYMVLUFQP-UHFFFAOYSA-N 0.000 claims 1
- XTUXRBOBAMIVKW-UHFFFAOYSA-N n-(4-ethynylphenyl)-5-methyl-6,7,8,9-tetrahydropyrazolo[1,5-a]quinazoline-3-carboxamide Chemical compound C1=NN2C=3CCCCC=3C(C)=NC2=C1C(=O)NC1=CC=C(C#C)C=C1 XTUXRBOBAMIVKW-UHFFFAOYSA-N 0.000 claims 1
- YLRWGWQIQUGXKC-UHFFFAOYSA-N n-(4-fluorophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(F)C=C1 YLRWGWQIQUGXKC-UHFFFAOYSA-N 0.000 claims 1
- ZVHPRYFJSAIMGK-UHFFFAOYSA-N n-(4-hydroxybutyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N1=C(C)C=C(C)N2N=CC(C(=O)NCCCCO)=C21 ZVHPRYFJSAIMGK-UHFFFAOYSA-N 0.000 claims 1
- NVEKWWBEUSXOPO-UHFFFAOYSA-N n-(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(I)C=C1 NVEKWWBEUSXOPO-UHFFFAOYSA-N 0.000 claims 1
- YLXANSGNXICBQB-UHFFFAOYSA-N n-(4-methoxy-2-methylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound CC1=CC(OC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 YLXANSGNXICBQB-UHFFFAOYSA-N 0.000 claims 1
- KUQXIIMOPRQJEU-UHFFFAOYSA-N n-(4-methoxyphenyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=C2N=C(C)C=C(C=3C=CC=CC=3)N2N=C1 KUQXIIMOPRQJEU-UHFFFAOYSA-N 0.000 claims 1
- GJRAHOAOYTUESK-UHFFFAOYSA-N n-(4-tert-butylcyclohexyl)-5-(difluoromethyl)-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=NN2C(C)=CC(C(F)F)=NC2=C1C(=O)NC1CCC(C(C)(C)C)CC1 GJRAHOAOYTUESK-UHFFFAOYSA-N 0.000 claims 1
- XZGHKSOOTBYBOO-UHFFFAOYSA-N n-(4-tert-butylcyclohexyl)-5-methyl-6,7,8,9-tetrahydropyrazolo[1,5-a]quinazoline-3-carboxamide Chemical compound C1=NN2C=3CCCCC=3C(C)=NC2=C1C(=O)NC1CCC(C(C)(C)C)CC1 XZGHKSOOTBYBOO-UHFFFAOYSA-N 0.000 claims 1
- OXLAZSHQAKWVMG-UHFFFAOYSA-N n-(4-tert-butylcyclohexyl)-5-methyl-7-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound N12N=CC(C(=O)NC3CCC(CC3)C(C)(C)C)=C2N=C(C)C=C1C1=CC=CC=C1 OXLAZSHQAKWVMG-UHFFFAOYSA-N 0.000 claims 1
- OSCNUENNIIXUMX-UHFFFAOYSA-N n-(4-tert-butylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1=CC=C(C(C)(C)C)C=C1 OSCNUENNIIXUMX-UHFFFAOYSA-N 0.000 claims 1
- VOSRZTXYBSYKBQ-UHFFFAOYSA-N n-(5-bromo-2-hydroxyphenyl)-5-cyclopropyl-7-(difluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound OC1=CC=C(Br)C=C1NC(=O)C1=C2N=C(C3CC3)C=C(C(F)F)N2N=C1 VOSRZTXYBSYKBQ-UHFFFAOYSA-N 0.000 claims 1
- YINWSUZLGIGNQA-UHFFFAOYSA-N n-(furan-2-ylmethyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NCC1=CC=CO1 YINWSUZLGIGNQA-UHFFFAOYSA-N 0.000 claims 1
- SNJGSROEIDCXQZ-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NCC1=CC=CC(Cl)=C1 SNJGSROEIDCXQZ-UHFFFAOYSA-N 0.000 claims 1
- FXXLLYDCMKSODH-UHFFFAOYSA-N n-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C1=CC(C#CCN(C)C)=CC=C1NC(=O)C1=C2N=C(C)C=C(C)N2N=C1 FXXLLYDCMKSODH-UHFFFAOYSA-N 0.000 claims 1
- VPAFDLGMOGSBOL-UHFFFAOYSA-N n-benzyl-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NCC1=CC=CC=C1 VPAFDLGMOGSBOL-UHFFFAOYSA-N 0.000 claims 1
- VETSUNZWTJUJCA-UHFFFAOYSA-N n-cyclohexyl-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C=12N=C(C)C=C(C)N2N=CC=1C(=O)NC1CCCCC1 VETSUNZWTJUJCA-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 11
- 206010064571 Gene mutation Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 10
- 210000003712 lysosome Anatomy 0.000 description 10
- 230000001868 lysosomic effect Effects 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 108010006519 Molecular Chaperones Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 102000005431 Molecular Chaperones Human genes 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- UWWGTDIBDPROEH-UHFFFAOYSA-N 5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound N1=C(C)C=C(C)N2N=CC(C(O)=O)=C21 UWWGTDIBDPROEH-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 108010028144 alpha-Glucosidases Proteins 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical class C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 208000015439 Lysosomal storage disease Diseases 0.000 description 4
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000007857 hydrazones Chemical class 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000707 stereoselective effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000005077 diacylhydrazine group Chemical group 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- YPXGHKWOJXQLQU-UHFFFAOYSA-N ethyl 5-amino-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1N YPXGHKWOJXQLQU-UHFFFAOYSA-N 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical class CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- ULBPPCHRAVUQMC-MUMXBIPUSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(3r,4r,5r)-5-(hydroxymethyl)piperidine-3,4-diol Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O.OC(=O)[C@H](O)[C@@H](O)C(O)=O ULBPPCHRAVUQMC-MUMXBIPUSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 description 1
- JXYITCJMBRETQX-UHFFFAOYSA-N 4-ethynylaniline Chemical compound NC1=CC=C(C#C)C=C1 JXYITCJMBRETQX-UHFFFAOYSA-N 0.000 description 1
- YUDPTGPSBJVHCN-YMILTQATSA-N 4-methylumbelliferyl beta-D-glucoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-YMILTQATSA-N 0.000 description 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C(*)=C(*)N1C)=NC1=*=C Chemical compound CC(C(*)=C(*)N1C)=NC1=*=C 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 101710116771 Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000008037 diacylhydrazines Chemical class 0.000 description 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- TTXVZCLTILVGML-UHFFFAOYSA-N ethyl 5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxylate Chemical compound CC1=CC(C)=NC2=C(C(=O)OCC)C=NN21 TTXVZCLTILVGML-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical group O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- XMRIUEGHBZTNND-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical class C1=CC=NC2=C(C(=O)N)C=NN21 XMRIUEGHBZTNND-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229940099072 zavesca Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42094610P | 2010-12-08 | 2010-12-08 | |
| US61/420,946 | 2010-12-08 | ||
| PCT/US2011/063928 WO2012078855A1 (en) | 2010-12-08 | 2011-12-08 | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013126094A RU2013126094A (ru) | 2015-01-20 |
| RU2603637C2 true RU2603637C2 (ru) | 2016-11-27 |
Family
ID=45498099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013126094/04A RU2603637C2 (ru) | 2010-12-08 | 2011-12-08 | Замещённые пиразолопиримидины как активаторы глюкоцереброзидазы |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9353117B2 (OSRAM) |
| EP (2) | EP2649075B1 (OSRAM) |
| JP (1) | JP6154746B2 (OSRAM) |
| KR (1) | KR101931224B1 (OSRAM) |
| CN (1) | CN103534255B (OSRAM) |
| AU (1) | AU2011338377B2 (OSRAM) |
| BR (1) | BR112013014242B1 (OSRAM) |
| CA (1) | CA2820362C (OSRAM) |
| CY (1) | CY1125186T1 (OSRAM) |
| DK (2) | DK2649075T3 (OSRAM) |
| ES (2) | ES2681218T3 (OSRAM) |
| HR (1) | HRP20220512T1 (OSRAM) |
| HU (1) | HUE038635T2 (OSRAM) |
| IL (2) | IL226767B (OSRAM) |
| LT (1) | LT3366688T (OSRAM) |
| MX (2) | MX385600B (OSRAM) |
| PL (2) | PL2649075T3 (OSRAM) |
| PT (2) | PT2649075T (OSRAM) |
| RS (1) | RS63320B1 (OSRAM) |
| RU (1) | RU2603637C2 (OSRAM) |
| SI (2) | SI2649075T1 (OSRAM) |
| TR (1) | TR201810523T4 (OSRAM) |
| WO (1) | WO2012078855A1 (OSRAM) |
| ZA (1) | ZA201304215B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2809824C1 (ru) * | 2023-09-08 | 2023-12-19 | Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт" - ПИЯФ) | Аллостерический фармакологический шаперон, восстанавливающий функцию глюкоцереброзидазы |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2649075T1 (sl) | 2010-12-08 | 2018-10-30 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Substituirani pirazolopirimidini kot aktivatorji glukocerebrozidaze |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US9845327B2 (en) * | 2011-06-22 | 2017-12-19 | The General Hospital Corporation | Treatment of proteinopathies |
| EP2723717A2 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| MX2013015058A (es) | 2011-06-24 | 2014-01-20 | Amgen Inc | Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos. |
| WO2013059587A1 (en) * | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| PT4190786T (pt) | 2012-12-07 | 2025-05-29 | Vertex Pharma | Compostos úteis como inibidores da quinase atr |
| JP2016512816A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| JP2016512239A (ja) | 2013-03-15 | 2016-04-25 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| MX389256B (es) | 2013-10-04 | 2025-03-20 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
| KR102575125B1 (ko) | 2014-06-05 | 2023-09-07 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 저해제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]-피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물의 방사성표지된 유도체, 상기 화합물의 제조 및 이의 다양한 고체 형태 |
| RU2736219C2 (ru) | 2014-06-17 | 2020-11-12 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации ингибиторов снк1 и atr |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX2017005586A (es) | 2014-11-03 | 2017-06-19 | Bayer Pharma AG | Piperidinilpirazolopirimidinonas y utilización de las mismas. |
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| KR102662215B1 (ko) * | 2014-11-06 | 2024-05-02 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 |
| ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
| EP3317282B1 (en) | 2015-07-01 | 2020-12-09 | Northwestern University | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
| WO2017040879A1 (en) * | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy |
| EP3344632A4 (en) * | 2015-09-04 | 2019-03-20 | Lysosomal Therapeutics Inc. | Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders |
| CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| EP3429590A4 (en) * | 2016-03-16 | 2020-02-19 | Lysosomal Therapeutics Inc. | METHOD AND COMPOSITIONS FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE IN A SUBJECT CARRIING THE SPHINGOLIPIDOSIS GENE |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| CA3020310A1 (en) * | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR20230104752A9 (ko) * | 2016-04-06 | 2024-11-15 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물및 의학적 장애의 치료에서의 그의 용도 |
| US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| EP3452455A4 (en) * | 2016-05-05 | 2019-11-13 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES |
| WO2017192929A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| JP7164774B2 (ja) * | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3535273A1 (en) * | 2016-11-02 | 2019-09-11 | H. Hoffnabb-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| EP3658557B1 (en) * | 2017-07-28 | 2024-06-05 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| US12291533B2 (en) | 2017-08-02 | 2025-05-06 | Northwestern University | Substituted fused pyrimidine compounds and uses thereof |
| ES2950757T3 (es) | 2017-10-06 | 2023-10-13 | Forma Therapeutics Inc | Inhibición de la peptidasa específica de la ubiquitina 30 |
| JP7317721B2 (ja) | 2018-01-31 | 2023-07-31 | 武田薬品工業株式会社 | 複素環化合物 |
| BR112020021921A2 (pt) | 2018-05-17 | 2021-01-26 | Forma Therapeutics, Inc. | compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina |
| US10882865B2 (en) | 2018-08-31 | 2021-01-05 | Northwestern University | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity |
| ES2938751T3 (es) | 2018-09-10 | 2023-04-14 | Lilly Co Eli | Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico |
| LT3860989T (lt) | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
| WO2020081508A1 (en) * | 2018-10-15 | 2020-04-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| AR117177A1 (es) | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| KR102821711B1 (ko) * | 2019-08-21 | 2025-06-16 | 더 스크립스 리서치 인스티튜트 | 인터페론 유전자의 자극인자 sting의 비시클릭 효능제 |
| CN114901652A (zh) | 2019-09-17 | 2022-08-12 | 比亚尔R&D投资股份公司 | 用于治疗医学病症的经取代的饱和和不饱和n-杂环甲酰胺及相关化合物 |
| WO2021055612A1 (en) | 2019-09-17 | 2021-03-25 | BIAL-BioTech Investments, Inc. | Substituted imidazole carboxamides and their use in the treatment of medical disorders |
| WO2021055627A1 (en) | 2019-09-17 | 2021-03-25 | Bial- Biotech Investments, Inc. | Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments |
| AU2020393174A1 (en) * | 2019-11-25 | 2022-06-30 | Gt Gain Therapeutics Sa | Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase |
| AR121251A1 (es) | 2020-02-12 | 2022-05-04 | Lilly Co Eli | Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| RU2378277C2 (ru) * | 2004-06-21 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг | Производные пиразолпиримидина |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037373A2 (en) | 2002-10-21 | 2004-05-06 | The Scripps Research Institute | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE |
| WO2004089471A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| CN1901907A (zh) | 2003-11-12 | 2007-01-24 | 阿米库斯治疗学公司 | 用于治疗戈谢病的葡糖并咪唑和多羟基环己烯基胺衍生物 |
| CA2507348C (en) * | 2004-05-13 | 2013-07-16 | The Hospital For Sick Children | Real time methylumbelliferone-based assay |
| DE602005007215D1 (de) * | 2004-05-14 | 2008-07-10 | Cleveland Clinic Foundation | Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter |
| DE102005007534A1 (de) * | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| US20070155737A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| KR20080087070A (ko) | 2005-05-20 | 2008-09-30 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제 |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| AU2006281497B2 (en) * | 2005-08-15 | 2012-06-07 | F. Hoffmann-La Roche Ag | Piperidine and piperazine derivatives as P2X3 antagonists |
| AU2006305104B2 (en) * | 2005-10-21 | 2009-10-22 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists |
| EP1948663B1 (en) * | 2005-10-21 | 2011-09-14 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
| WO2008054947A2 (en) | 2006-10-02 | 2008-05-08 | The Brigham And Women's Hospital, Inc. | Structure of acid beta-glucosidase and methods for identifying therapeutic agents |
| US20090275586A1 (en) | 2006-10-06 | 2009-11-05 | Kalypsys, Inc. | Heterocyclic inhibitors of pde4 |
| EP2102211A2 (en) | 2006-11-20 | 2009-09-23 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2008128106A1 (en) | 2007-04-13 | 2008-10-23 | Amicus Therapeutics, Inc. | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| US20090215778A1 (en) | 2007-04-27 | 2009-08-27 | Panacos Pharmaceuticals, Inc. | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives |
| HUE027278T2 (en) | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| US20090118135A1 (en) | 2007-06-08 | 2009-05-07 | The Burnham Institute | Methods and compounds for regulating apoptosis |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| WO2009049421A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP5767965B2 (ja) * | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症 |
| WO2010003023A2 (en) | 2008-07-01 | 2010-01-07 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| WO2010086040A1 (en) * | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| SI2649075T1 (sl) * | 2010-12-08 | 2018-10-30 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Substituirani pirazolopirimidini kot aktivatorji glukocerebrozidaze |
| KR102662215B1 (ko) * | 2014-11-06 | 2024-05-02 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 |
-
2011
- 2011-12-08 SI SI201131532T patent/SI2649075T1/sl unknown
- 2011-12-08 LT LTEP18165005.2T patent/LT3366688T/lt unknown
- 2011-12-08 EP EP11810714.3A patent/EP2649075B1/en active Active
- 2011-12-08 PT PT118107143T patent/PT2649075T/pt unknown
- 2011-12-08 DK DK11810714.3T patent/DK2649075T3/en active
- 2011-12-08 JP JP2013543335A patent/JP6154746B2/ja active Active
- 2011-12-08 SI SI201132052T patent/SI3366688T1/sl unknown
- 2011-12-08 US US13/991,816 patent/US9353117B2/en active Active
- 2011-12-08 PL PL11810714T patent/PL2649075T3/pl unknown
- 2011-12-08 RU RU2013126094/04A patent/RU2603637C2/ru active
- 2011-12-08 BR BR112013014242-1A patent/BR112013014242B1/pt active IP Right Grant
- 2011-12-08 DK DK18165005.2T patent/DK3366688T3/da active
- 2011-12-08 CN CN201180066859.7A patent/CN103534255B/zh active Active
- 2011-12-08 PT PT181650052T patent/PT3366688T/pt unknown
- 2011-12-08 HR HRP20220512TT patent/HRP20220512T1/hr unknown
- 2011-12-08 KR KR1020137017520A patent/KR101931224B1/ko active Active
- 2011-12-08 ES ES11810714.3T patent/ES2681218T3/es active Active
- 2011-12-08 MX MX2018000385A patent/MX385600B/es unknown
- 2011-12-08 HU HUE11810714A patent/HUE038635T2/hu unknown
- 2011-12-08 RS RS20220422A patent/RS63320B1/sr unknown
- 2011-12-08 ES ES18165005T patent/ES2912284T3/es active Active
- 2011-12-08 PL PL18165005T patent/PL3366688T3/pl unknown
- 2011-12-08 EP EP18165005.2A patent/EP3366688B1/en active Active
- 2011-12-08 TR TR2018/10523T patent/TR201810523T4/tr unknown
- 2011-12-08 MX MX2013006462A patent/MX354506B/es active IP Right Grant
- 2011-12-08 CA CA2820362A patent/CA2820362C/en active Active
- 2011-12-08 AU AU2011338377A patent/AU2011338377B2/en active Active
- 2011-12-08 WO PCT/US2011/063928 patent/WO2012078855A1/en not_active Ceased
-
2013
- 2013-06-06 IL IL226767A patent/IL226767B/en active IP Right Grant
- 2013-06-07 ZA ZA2013/04215A patent/ZA201304215B/en unknown
-
2016
- 2016-04-28 US US15/141,275 patent/US9974789B2/en active Active
-
2018
- 2018-05-18 US US15/983,844 patent/US10925874B2/en active Active
- 2018-05-28 IL IL259648A patent/IL259648B/en active IP Right Grant
-
2022
- 2022-05-04 CY CY20221100316T patent/CY1125186T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| RU2378277C2 (ru) * | 2004-06-21 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг | Производные пиразолпиримидина |
Non-Patent Citations (50)
| Title |
|---|
| ) 831193-09-0 (Entered * |
| ) и 897764-74-8 (Entered * |
| ), (Entered * |
| ), 309745-60-6 (Entered * |
| ), 312635-20-4 (Entered * |
| ), 313397-13-6 (Entered * |
| ), 348163-90-6 и 348163-84-8 (Entered * |
| ), 351521-17-0 (Entered * |
| ), 355133-51-6 (Entered * |
| ), 438223-28-0 (Entered * |
| ), 438223-66-6 (Entered * |
| ), 438223-91-7 (Entered * |
| ), 4450031-91-4 (Entered * |
| ), 445036-05-5 (Entered * |
| ), 445038-07-3 (Entered * |
| ), 445038-98-2 (Entered * |
| ), 445239-64-5 (Entered * |
| ), 492427-56-2 (Entered * |
| ), 515857-38-2 (Entered * |
| ), 515857-92-8 (Entered * |
| ), 515858-01-2 (Entered * |
| ), 515858-02-3 (Entered * |
| ), 5158849-83-9 (Entered * |
| ), 664992-06-7 (Entered * |
| ), 664992-24-9 (Entered * |
| ), 675151-49-2 (Entered * |
| ), 676244-99-8 (Entered * |
| ), 676439-58-0 (Entered * |
| ), 677735-72-7 (Entered * |
| ), 677845-76-8 (Entered * |
| ), 688769-83-7 (Entered * |
| ), 725696-66-2 (Entered * |
| ), 725696-69-5 (Entered * |
| ), 725696-75-3 (Entered * |
| ), 797806-33-8 (Entered * |
| ), 831185-24-1 (Entered * |
| ), 831207-46-6 (Entered * |
| ), 835887-95-1 (Entered * |
| ), 836665-83-9 (Entered * |
| ), DATABASE CA, STN [Online], соединения с 830349-04-7 (Entered * |
| ), и 515848-93-3 (Entered * |
| ). HUPPATZ J.L. ET AL ";Systemic fungicides. The Synthesis of Pyrazolo[1,5-a]pyrimidine Analogues of Carboxin";, Australian Journal of Chemistry, 1985, vol. 38, pp.221-30, соединения (11), 12, (14), (15), и (17)-(18). DATABASE CA, STN [Online], соединение с RN CAS RN 933237-02-7 (Entered * |
| 688776-93-4, 688776-91-2, 688776-95-6, 688776-92-3 (Entered * |
| 848432-93-9, 848432-79-1, 848432-42-8, 848431-57-2 (Entered * |
| DALINGER IGOR L. ET AL ";Liquid-Phase Synthesis of Combinatorial Libraries Based on 7-Trifluoromethyl-Substituted Pyrazolo[1,5-a]Pyrimidine Scaffold";, Journal of Combinatorial Chemistry, 2005, vol.7, pp. 236-245 & DATABASE CA, STN [Online], соединения с * |
| DATABASE CA, STN [Online], соединения с * |
| DATABASE CA, STN [Online], соединения с RN CAS 5128811-24-4 (Entered * |
| DATABASE CA, STN [Online], соединения с RN CAS 515849-88-4 (Entered * |
| DATABASE CA, STN [Online], соединения с RN CAS 515850-36-9 (Entered * |
| DATABASE CA, STN [Online], соединения с RN CAS 688776-89-8 (Entered * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2809824C1 (ru) * | 2023-09-08 | 2023-12-19 | Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт" - ПИЯФ) | Аллостерический фармакологический шаперон, восстанавливающий функцию глюкоцереброзидазы |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2603637C2 (ru) | Замещённые пиразолопиримидины как активаторы глюкоцереброзидазы | |
| US12325710B2 (en) | Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders | |
| RU2346945C2 (ru) | Производные n-гетероциклилметилбензамидов, их получение и их применение в терапии | |
| CN112313231B (zh) | Oga抑制剂化合物 | |
| JP2014532619A (ja) | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 | |
| BG108487A (bg) | Заместени с триамид индоли, бензофурани и бензотиофени като инхибитори на микрозомния триглицерид пренасящ протеин (mtp) и/или секрецията на аполипопротеин б (аро в) | |
| AU2012224632A1 (en) | 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | |
| KR20150037950A (ko) | 4-메틸-2,3,5,9,9ｂ-펜타아자-사이클로펜타[ａ]나프탈렌 | |
| EP3577121A1 (en) | Oga inhibitor compounds | |
| EP3697781B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| TW202416989A (zh) | 作為pi3k抑制劑的苯并嘧啶-4(3h)-酮 | |
| KR20090031333A (ko) | 신규한 베타-세크리타제 저해용 화합물 | |
| US20070161628A1 (en) | Phosphodiesterase inhibitors | |
| HUT70148A (en) | Isoquinolone derivatives as techykinin receptor antagonists, process for producing thereof and pharmaceutical compositions comprising them | |
| KR101627602B1 (ko) | 2-메틸-2ｈ-크로멘-2-카르복사미드 화합물 | |
| JP2020514284A (ja) | イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用 | |
| CA2564489A1 (en) | Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity | |
| WO2021110656A1 (en) | Oga inhibitor compounds | |
| NZ615720B2 (en) | 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |